Deltex Medical Group (DEMG)

Sector:

Health Care

Index:

FTSE AIM All-Share

   Trade now with Barclays Stockbrokers   Trade now with Barclays   Sponsored by Barclays Stockbrokers

 1.23p
   
  • Change Today:
      0.000p
  • 52 Week High: 2.38p
  • 52 Week Low: 0.76p
  • Currency: UK Pounds
  • Shares Issued: 492.66m
  • Volume: 212,000
  • Market Cap: £6.04m
  • RiskGrade: 447
  • Beta: 0.60

Deltex Medical appoints new chief executive as Ewan Phillips steps down

By Duncan Ferris

Date: Wednesday 13 Jun 2018

LONDON (ShareCast) - (Sharecast News) - Oesophageal doppler monitoring firm Deltex Medical Group on Wednesday appointed Andy Mears as chief executive after Ewan Phillips resigned as from the role.
Mears will take over the role with immediate effect after Phillips approached the AIM traded company's chairman with the assertion that there should be a change in leadership to guide the group through its next stage of development.

Nigel Keen, chairman of Deltex, said: "I want to thank Ewan Phillips for his work and dedication to Deltex over the last 17 years, the second half of these as chief executive. During this time the group has expanded significantly the evidence base which demonstrates the superior data generated for clinicians by Deltex's oesophageal doppler monitoring technology."

According to Deltex, Phillips felt that following a successful fundraising in February, recent cost reductions and the launch of the TrueVue platform, the company is now well-positioned for the future.

Currently the managing director of Deltex Medical Limited, Deltex Medical Group's principal operating subsidiary, Mears started at Deltex as an engineer in 1989 before working in a number of operational roles.

In his current role, he oversees international sales and the company's key opinion leader development programmes.

"I am delighted that Andy Mears has accepted the role of Chief Executive and I look forward to working closely with him to drive forwards the recently launched TrueVue platform from an improved financial footing," said Keen.

As of 1553 BST, Deltex Medical Group's shares were unchanged at 1.30p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

DEMG Market Data

Currency UK Pounds
Share Price 1.23p
Change Today 0.000p
% Change 0.00 %
52 Week High 2.38p
52 Week Low 0.76p
Volume 212,000
Shares Issued 492.66m
Market Cap £6.04m
Beta 0.60
RiskGrade 447

DEMG Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
47.68% below the market average47.68% below the market average47.68% below the market average47.68% below the market average47.68% below the market average
17.65% below the sector average17.65% below the sector average17.65% below the sector average17.65% below the sector average17.65% below the sector average
Price Trend
66.5% below the market average66.5% below the market average66.5% below the market average66.5% below the market average66.5% below the market average
62.16% below the sector average62.16% below the sector average62.16% below the sector average62.16% below the sector average62.16% below the sector average
Income Not Available
Growth
50.91% below the market average50.91% below the market average50.91% below the market average50.91% below the market average50.91% below the market average
58.82% below the sector average58.82% below the sector average58.82% below the sector average58.82% below the sector average58.82% below the sector average

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 1
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

DEMG Dividends

No dividends found

Trades for 15-Nov-2018

Time Volume / Share Price
15:58 200,000 @ 1.20p
12:16 12,000 @ 1.25p

DEMG Key Personnel

Chair Nigel J Keen
Finance Director Jonathan David Shaw
CEO Andy Mears

Top of Page